Welcome to our dedicated page for Treatment.com AI news (Ticker: TREIF), a resource for investors and traders seeking the latest updates and insights on Treatment.com AI stock.
Treatment.com AI Inc. (TREIF) is a pioneering force in AI-driven healthcare solutions, merging clinical expertise with advanced technology to transform medical education and diagnostic support. This page serves as the definitive source for official company announcements, strategic developments, and milestone updates.
Investors and healthcare professionals will find curated news on TREIF's Global Library of Medicine (GLM) advancements, Medical Education Suite (MES) implementations, and partnerships shaping AI integration in clinical environments. Key updates include product launches, clinical validation milestones, and collaborations with medical institutions.
Our repository provides immediate access to earnings reports, technology licensing agreements, and regulatory filings. All content is vetted for accuracy, offering reliable insights into TREIF's role in reducing diagnostic errors and streamlining medical training processes through AI innovation.
Bookmark this page for real-time updates on TREIF's contributions to healthcare technology. For comprehensive tracking of the company's progress in AI-powered clinical decision tools and educational solutions, revisit regularly or subscribe to alerts.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces its participation in the 2024 Cantech Letter Investment Conference on October 9, 2024 in Toronto, Ontario. CEO Dr. Essam Hamza will deliver an investor presentation at 11:00 AM ET and participate in 1-on-1 meetings with investors. The event will take place at the Arcadian Loft, 8th floor, 401 Bay Street.
Dr. Hamza emphasized the conference's importance, stating, "The healthcare system is at the precipice of substantial modernization and we believe that our proprietary platform can help with reducing its inefficiencies, reducing administration headaches, and ultimately improving patient access and care." Interested parties can contact tara@cantechletter.com to register or schedule 1-on-1 meetings with Treatment.com AI.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided updates on its marketing engagements and focus on AI in medical education. The company has extended its agreement with Leit Media for investor relations services, adding an additional EUR 250,000 for a digital marketing campaign targeting German-speaking investors. Treatment.com has also engaged Interactive Media Group (IMG) for a one-month marketing awareness program for US$23,000.
The company highlighted the global adoption of the Objective Structured Clinical Examination (OSCE) in over 80 countries, with an estimated 200,000-300,000 medical students taking the exam annually. Treatment.com has been providing OSCE services to medical schools, including the University of Minnesota, for the past three years.
Treatment.com will be a lead participant in an upcoming Symposium on AI Assessment in Medical Education. The company is also on track to release two new SaaS solutions in H2 2024: AI Patient and AI Doctor in a Pocket, aimed at supporting medical students and healthcare professionals.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has signed a Collaborative Agreement with SPRYT to explore AI-powered solutions for healthcare challenges. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with SPRYT's AI Medical Office Assistant, Asa, to create an innovative patient onboarding and triaging tool. This collaboration targets reducing administrative costs, which account for 25% ($1 trillion) of annual US healthcare spending, and addressing the $150 billion annual cost of missed appointments.
The partnership aims to improve patient access, reduce healthcare system costs, and streamline processes for healthcare professionals. SPRYT's Asa allows patients to book and manage appointments via messaging apps, while Treatment's GLM provides comprehensive medical history and diagnosis suggestions. The collaboration will focus on developing solutions for markets in the UK, North America, and the Middle East.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has signed a Collaborative Agreement with the University of Edinburgh to utilize Treatment's proprietary Global Library of Medicine (GLM) in the SET4 Systems Engineering initiative. This multi-million dollar project aims to transform long-term care services across the UK, focusing on improving transitions in health and social care for people with Multiple Long-Term Conditions (MLTC).
The collaboration leverages the University of Edinburgh's top-ranking status in industry innovation and infrastructure. The project will initially focus on specific communities in Scotland, with the goal of wider adoption across the UK National Health Service (NHS) and other social care settings. Both parties will also explore additional collaborative and commercial opportunities to enhance healthcare system efficiency and patient care.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) endorses recent recommendations from a Washington roundtable on AI in healthcare. The company's AI-powered Global Library of Medicine (GLM) aims to address key challenges in healthcare, including:
- Alleviating workforce burdens
- Improving efficiency and patient outcomes
- Ensuring equitable access for patients and care teams
The GLM provides high-level clinical support to healthcare professionals, enhancing diagnostic accuracy and transparency. It operates in a secure environment, allowing Large Language Models to query trusted content, reducing risks of misdiagnosis and bias. The platform aims to streamline tasks for healthcare professionals, potentially impacting costs and efficiency for healthcare organizations.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced a new AI Pharmacy Assistant solution, set to launch in 2024. This tool aims to support pharmacists in their expanding role in healthcare, particularly in providing clinical decision support services. The AI Pharmacy Assistant is powered by Treatment's proprietary Global Library of Medicine (GLM), offering features such as:
- Automated patient history and symptom recording
- Documentation of patient interactions
- Enhanced diagnostic support
- Error minimization and increased clinical efficiency
- Comprehensive diagnostic information backed by up-to-date medical research
The global clinical decision support systems market is projected to grow from $2.46 billion in 2024 to $4.05 billion by 2029. This new product line represents an additional revenue stream for Treatment.com AI's GLM platform.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced a new AI Pharmacy Assistant solution, set to launch in 2024. This tool aims to support pharmacists in their expanding role within healthcare systems globally. The AI assistant, powered by Treatment's proprietary Global Library of Medicine (GLM), will help pharmacists by:
- Reducing time for patient history and symptom collection
- Automatically documenting patient interactions
- Extending diagnostic support capabilities
- Minimizing errors and increasing clinical efficiency
- Providing up-to-date medical research
The global clinical decision support systems market is projected to grow from $2.46 billion in 2024 to $4.05 billion by 2029. Treatment.com AI's CEO, Dr. Essam Hamza, emphasizes the product's potential to improve efficiency for payers, support pharmacists, and enhance patient care access.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will help expedite the company's plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI has also mentioned a strong acquisition pipeline under review, which could accelerate their growth strategy.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will enable the company to expedite its plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI also has a strong acquisition pipeline under review, which could accelerate their growth strategy. The company's core product is the Global Library of Medicine (GLM), an AI-driven healthcare engine providing clinical information with >92% accuracy on first diagnosis.
Treatment AI has provided a corporate update outlining significant progress and milestones. Financially, the company completed an oversubscribed private placement, raising $2.91M, and settled $1.1M in debt, becoming debt-free. New partnerships with aiXplain and Novus Health aim to enhance the Global Library of Medicine (GLM) and develop new healthcare solutions. A trial demonstrated GLM’s high diagnostic accuracy with a 92% success rate. The company expanded its executive team with Richard Atkins as COO and Dr. Jean Challiner as Executive Advisor, enhancing expertise in digital health and clinical decision support. Additionally, two new AI-driven SaaS solutions, AI Patient and AI Doctor in Your Pocket, are set for release in H2 2024.
FAQ
What is the current stock price of Treatment.com AI (TREIF)?
What is the market cap of Treatment.com AI (TREIF)?
